Install
Stay informed on the latest biopharmaceutical news, trends, and developments in Asia Pacific with BioPharma APAC. BioPharma Asia ( APAC ) provides in-depth analysis, insights, and expert commentary on drug development, regulatory updates, and industry partnerships in the region.
- 665articles · 180d
- 2+ day agolatest article
- Mar 23, 2026earliest in window
- 93%with images
- 260avg words
- Medical 427
- Health & Wellness 354
- Health 253
- Business & Industrial 245
- Economy, Business & Finance 230
- Science & Technology 171
- Science & Nature 134
- Finance & Business 64
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Kelun-Biotech’s Twice-Yearly Asthma Candidate SKB378 Advances into Phase III
3+ day, 8+ hour ago (143+ words) 10 September 2026 | Thursday | News Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that its partner, Windward Bio, has reported positive interim results from the Phase 2 portion of the POLARIS-1 clinical trial, which evaluates twice-yearly dosing of SKB378/WIN378 in asthma. The…...
Convergen Raises $15M Seed+ to Accelerate Targeted Protein Degradation Therapies
1+ week, 4+ day ago (60+ words) 02 September 2026 | Wednesday | News The proceeds will be used to further advance Convergen's proprietary degrader platform and accelerate its pipeline for neurodegenerative disorders and other protein aggregation diseases. Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence China Plus…...
Thermo Fisher Strengthens China Focus as Biopharma Innovation Gains Global Momentum
1+ week, 5+ day ago (344+ words) 01 September 2026 | Tuesday | News Thermo Fisher Scientific is reinforcing its commitment to China as the country emerges as an increasingly important source of global biopharmaceutical innovation, with Chairman and CEO Marc Casper highlighting opportunities to support Chinese drug developers across discovery,…...
DualityBio, Genentech Ink $1B-Plus Deal to Develop Next-Generation ADCs Against Drug-Resistant Tumours
1+ week, 6+ day ago (234+ words) 31 August 2026 | Monday | News DUALITYBIO Inc. announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates ("ADCs") built on the Company's proprietary DualityBio Unique Payload Antibody Conjugate…...
HiRO and Differentia Join Forces to Advance AI-Powered Clinical Trial Simulation and Digital Twins
1+ week, 6+ day ago (189+ words) 31 August 2026 | Monday | News L-R: Karen Chu, CEO & Founder, HiRO; Shirley Wen, Founder, Differentia Biotech At a time when biopharma R&D productivity is declining and the cost of bringing a single drug to market exceeds $2.6 billion, two companies are converging…...
South Korea’s Rznomics Joins Lilly Gateway Labs in US to Accelerate RNA Gene Therapies
2+ week, 5+ day ago (159+ words) 24 August 2026 | Monday | News Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Through its entry into Lilly Gateway Labs, Rznomics plans to…...
Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1
2+ week, 6+ day ago (172+ words) 24 August 2026 | Monday | News AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 (TROP2/Nectin-4 ADC) and AK138D1 (HER3 ADC). The clearance further advances the Company's IO2.0 + ADC2.0 strategy and expands its broad innovative oncology pipeline. B7-H3 is highly expressed in a broad…...
AbelZeta Secures US FDA IND Clearance for Bispecific CAR-T Therapy C-CAR039 in Large B-cell Lymphoma
3+ week, 5+ day ago (58+ words) 18 August 2026 | Tuesday | News The registrational Phase II clinical trial of C-CAR039 for r/r LBCL in CAR-T therapy naïve patients in China is still ongoing. Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence China Plus One: Slogan, Strategy,…...
Insilico Nominates AI-Designed ISM0900 as Preclinical Candidate for Cardiovascular Risk
4+ week, 2+ day ago (163+ words) 14 August 2026 | Friday | News In preclinical studies, ISM0900 demonstrates potent and selective inhibition of Lp(a) assembly at nanomolar-level activity, along with more rapid onset in animal models, excellent oral pharmacokinetic properties, and superior efficacy compared to clinical-stage candidates of the same class....
Aureka Biotechnologies Raises $100M Series B to Advance AI-Driven Drug Discovery
1+ mon, 1+ day ago (494+ words) 12 August 2026 | Wednesday | News Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, and a prominent strategic investor led a subsequent tranche, with participation from HighLight Capital (HLC) and…...